Company Overview - Silo Pharma Inc is a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, particularly for stress-induced psychiatric disorders, chronic pain, and CNS diseases [1][4] - The company's portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [4] - Silo Pharma collaborates with leading universities and laboratories for its research [4] Intellectual Property and Pipeline Development - Silo Pharma filed a provisional patent application with the USPTO for its lead asset SPC-15, targeting NMDARs and 5-HT4Rs to address stress-induced psychiatric disorders [1][2] - The patent application aims to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia [2] - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist with potential eligibility for the FDA's 505(b)(2) regulatory pathway, which could accelerate approval [3] - The company has exclusive global rights to develop and commercialize SPC-15 through a collaboration with Columbia University [2][3] Strategic Focus and Leadership Commentary - Silo Pharma's intellectual property strategy is a cornerstone of its growth, with the latest provisional patent reinforcing strong IP protection for SPC-15 [3] - The company aims to deliver innovative therapies for patients with PTSD and other stress-induced disorders [3]
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment